Iptacopan
Last Updated: 02/24/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 126 publications
Advancing treatment goals for paroxysmal nocturnal hemoglobinuria to align with quality of life improvements in the era of anti-complement therapy
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
Published: January 12, 2026
Cost per responder analysis of iptacopan versus eculizumab and ravulizumab in treatment of paroxysmal nocturnal hemoglobinuria: implications for decision-making.
Journal: Journal of medical economics
Published: January 10, 2026
Discovery of (3R,4R)-15: An Advanced Factor B Inhibitor Entering Phase 3 for Complement-Mediated Diseases.
Journal: Journal of medicinal chemistry
Published: January 09, 2026
Nephrology highlights in 2025: Diagnostic and therapeutic advances and emerging challenges
Journal: Nephrologie & therapeutique
Published: January 06, 2026
Emerging Therapies in IgA Nephropathy: From A Proliferation-Inducing Ligand (APRIL) and B-cell Activating Factor (BAFF) Inhibitors to Precision Medicine.
Journal: Cureus
Published: December 21, 2025
C3 glomerulopathy: advancements in diagnostics and therapeutics.
Journal: Current opinion in nephrology and hypertension
Published: November 10, 2025
Iptacopan for paroxysmal nocturnal haemoglobinuria.
Journal: Australian prescriber
Published: October 30, 2025
Iptacopan for Immune Thrombocytopenia and Cold Agglutinin Disease: A Global Phase 2 Basket Clinical Trial.
Journal: American journal of hematology
Published: October 27, 2025
Progress in the use of biological therapies to treat paroxysmal nocturnal hemoglobinuria: focus on patient profiling.
Journal: Expert opinion on biological therapy
Published: October 13, 2025
IgA Nephropathy: An Overview of the Clinical Trials.
Journal: Kidney medicine
Published: October 06, 2025
Challenges in optimizing targeted complement inhibitor therapy for paroxysmal nocturnal hemoglobinuria in an expanding treatment landscape
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
Published: October 01, 2025
Successful switch from pegcetacoplan to iptacopan after repeated severe breakthrough hemolysis events - case report.
Journal: Hematology (Amsterdam, Netherlands)
Published: September 20, 2025
Last Updated: 02/24/2026